Loading…

Understanding RAGE, the receptor for advanced glycation end products

Advanced glycation end products (AGEs), S100/calgranulins, HMGB1-proteins, amyloid-beta peptides, and the family of beta-sheet fibrils have been shown to contribute to a number of chronic diseases such as diabetes, amyloidoses, inflammatory conditions, and tumors by promoting cellular dysfunction vi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of molecular medicine (Berlin, Germany) Germany), 2005-11, Vol.83 (11), p.876-886
Main Authors: BIERHAUS, Angelika, HUMPERT, Per M, MORCOS, Michael, WENDT, Thoralf, CHAVAKIS, Triantafyllos, ARNOLD, Bernd, STERN, David M, NAWROTH, Peter P
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c422t-97e9f7ac59a04e2f9eaaac3703f6a4f199821cc88f382c8dfb769b67db0c3fe43
cites cdi_FETCH-LOGICAL-c422t-97e9f7ac59a04e2f9eaaac3703f6a4f199821cc88f382c8dfb769b67db0c3fe43
container_end_page 886
container_issue 11
container_start_page 876
container_title Journal of molecular medicine (Berlin, Germany)
container_volume 83
creator BIERHAUS, Angelika
HUMPERT, Per M
MORCOS, Michael
WENDT, Thoralf
CHAVAKIS, Triantafyllos
ARNOLD, Bernd
STERN, David M
NAWROTH, Peter P
description Advanced glycation end products (AGEs), S100/calgranulins, HMGB1-proteins, amyloid-beta peptides, and the family of beta-sheet fibrils have been shown to contribute to a number of chronic diseases such as diabetes, amyloidoses, inflammatory conditions, and tumors by promoting cellular dysfunction via binding to cellular surface receptors. The receptor for AGEs (RAGE) is a multiligand receptor of the immunoglobulin superfamily of cell surface molecules acting as counter-receptor for these diverse molecules. Engagement of RAGE converts a brief pulse of cellular activation to sustained cellular dysfunction and tissue destruction. The involvement of RAGE in pathophysiologic processes has been demonstrated in murine models of chronic disease using either a receptor decoy such as soluble RAGE (sRAGE), RAGE neutralizing antibodies, or a dominant-negative form of the receptor. Studies with RAGE-/- mice confirmed that RAGE contributes, at least in part, to the development of late diabetic complications, such as neuropathy and nephropathy, macrovascular disease, and chronic inflammation. Furthermore, deletion of RAGE provided protection from the lethal effects of septic shock caused by cecal ligation and puncture (CLP). In contrast, deletion of RAGE had no effect on the host response in delayed-type hypersensitivity (DTH). Despite the lack of effect seen in adaptive immunity by the deletion of RAGE, administration of the receptor decoy, sRAGE, still afforded a protective effect in RAGE-/- mice. Thus, sRAGE is likely to sequester ligands, thereby preventing their interaction with other receptors in addition to RAGE. These data suggest that, just as RAGE is a multiligand receptor, its ligands are also likely to recognize several receptors in mediating their biologic effects.
doi_str_mv 10.1007/s00109-005-0688-7
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68799494</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68799494</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-97e9f7ac59a04e2f9eaaac3703f6a4f199821cc88f382c8dfb769b67db0c3fe43</originalsourceid><addsrcrecordid>eNpdkMlKA0EQhhtRTFwewIsMgp4crV7SyzHEuIAgiJ6bnl7ihMlM7J4RfHs7JBDwUNTl-_8qPoQuMNxhAHGfADCoEmBSApeyFAdojBklJWYMDtEYFOMlEZiP0ElKy0yLiWLHaIQ5ppQRPkYPn63zMfWmdXW7KN6nT_Pbov_yRfTWr_suFiGPcT-mtd4Vi-bXmr7u2sK3rljHzg22T2foKJgm-fPdPkWfj_OP2XP5-vb0Mpu-lpYR0pdKeBWEsRNlgHkSlDfGWCqABm5YwEpJgq2VMlBJrHShElxVXLgKLA2e0VN0s-3Nh78Hn3q9qpP1TWNa3w1JcymUYmoDXv0Dl90Q2_ybJlgImHDCM4S3kI1dStEHvY71ysRfjUFv_OqtX5396o1fLXLmclc8VCvv9omd0Axc7wCTrGlCzN7qtOcEkQIkp384i4IR</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217705626</pqid></control><display><type>article</type><title>Understanding RAGE, the receptor for advanced glycation end products</title><source>Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List</source><creator>BIERHAUS, Angelika ; HUMPERT, Per M ; MORCOS, Michael ; WENDT, Thoralf ; CHAVAKIS, Triantafyllos ; ARNOLD, Bernd ; STERN, David M ; NAWROTH, Peter P</creator><creatorcontrib>BIERHAUS, Angelika ; HUMPERT, Per M ; MORCOS, Michael ; WENDT, Thoralf ; CHAVAKIS, Triantafyllos ; ARNOLD, Bernd ; STERN, David M ; NAWROTH, Peter P</creatorcontrib><description>Advanced glycation end products (AGEs), S100/calgranulins, HMGB1-proteins, amyloid-beta peptides, and the family of beta-sheet fibrils have been shown to contribute to a number of chronic diseases such as diabetes, amyloidoses, inflammatory conditions, and tumors by promoting cellular dysfunction via binding to cellular surface receptors. The receptor for AGEs (RAGE) is a multiligand receptor of the immunoglobulin superfamily of cell surface molecules acting as counter-receptor for these diverse molecules. Engagement of RAGE converts a brief pulse of cellular activation to sustained cellular dysfunction and tissue destruction. The involvement of RAGE in pathophysiologic processes has been demonstrated in murine models of chronic disease using either a receptor decoy such as soluble RAGE (sRAGE), RAGE neutralizing antibodies, or a dominant-negative form of the receptor. Studies with RAGE-/- mice confirmed that RAGE contributes, at least in part, to the development of late diabetic complications, such as neuropathy and nephropathy, macrovascular disease, and chronic inflammation. Furthermore, deletion of RAGE provided protection from the lethal effects of septic shock caused by cecal ligation and puncture (CLP). In contrast, deletion of RAGE had no effect on the host response in delayed-type hypersensitivity (DTH). Despite the lack of effect seen in adaptive immunity by the deletion of RAGE, administration of the receptor decoy, sRAGE, still afforded a protective effect in RAGE-/- mice. Thus, sRAGE is likely to sequester ligands, thereby preventing their interaction with other receptors in addition to RAGE. These data suggest that, just as RAGE is a multiligand receptor, its ligands are also likely to recognize several receptors in mediating their biologic effects.</description><identifier>ISSN: 0946-2716</identifier><identifier>EISSN: 1432-1440</identifier><identifier>DOI: 10.1007/s00109-005-0688-7</identifier><identifier>PMID: 16133426</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Animals ; Biological and medical sciences ; Chronic Disease ; Diabetes Mellitus - metabolism ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; General aspects ; Glycation End Products, Advanced - metabolism ; Humans ; Immunity - physiology ; Medical sciences ; NF-kappa B - drug effects ; NF-kappa B - metabolism ; Receptor for Advanced Glycation End Products ; Receptors, Immunologic - drug effects ; Receptors, Immunologic - physiology ; Signal Transduction - physiology</subject><ispartof>Journal of molecular medicine (Berlin, Germany), 2005-11, Vol.83 (11), p.876-886</ispartof><rights>2006 INIST-CNRS</rights><rights>Springer-Verlag 2005</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-97e9f7ac59a04e2f9eaaac3703f6a4f199821cc88f382c8dfb769b67db0c3fe43</citedby><cites>FETCH-LOGICAL-c422t-97e9f7ac59a04e2f9eaaac3703f6a4f199821cc88f382c8dfb769b67db0c3fe43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17287086$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16133426$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BIERHAUS, Angelika</creatorcontrib><creatorcontrib>HUMPERT, Per M</creatorcontrib><creatorcontrib>MORCOS, Michael</creatorcontrib><creatorcontrib>WENDT, Thoralf</creatorcontrib><creatorcontrib>CHAVAKIS, Triantafyllos</creatorcontrib><creatorcontrib>ARNOLD, Bernd</creatorcontrib><creatorcontrib>STERN, David M</creatorcontrib><creatorcontrib>NAWROTH, Peter P</creatorcontrib><title>Understanding RAGE, the receptor for advanced glycation end products</title><title>Journal of molecular medicine (Berlin, Germany)</title><addtitle>J Mol Med (Berl)</addtitle><description>Advanced glycation end products (AGEs), S100/calgranulins, HMGB1-proteins, amyloid-beta peptides, and the family of beta-sheet fibrils have been shown to contribute to a number of chronic diseases such as diabetes, amyloidoses, inflammatory conditions, and tumors by promoting cellular dysfunction via binding to cellular surface receptors. The receptor for AGEs (RAGE) is a multiligand receptor of the immunoglobulin superfamily of cell surface molecules acting as counter-receptor for these diverse molecules. Engagement of RAGE converts a brief pulse of cellular activation to sustained cellular dysfunction and tissue destruction. The involvement of RAGE in pathophysiologic processes has been demonstrated in murine models of chronic disease using either a receptor decoy such as soluble RAGE (sRAGE), RAGE neutralizing antibodies, or a dominant-negative form of the receptor. Studies with RAGE-/- mice confirmed that RAGE contributes, at least in part, to the development of late diabetic complications, such as neuropathy and nephropathy, macrovascular disease, and chronic inflammation. Furthermore, deletion of RAGE provided protection from the lethal effects of septic shock caused by cecal ligation and puncture (CLP). In contrast, deletion of RAGE had no effect on the host response in delayed-type hypersensitivity (DTH). Despite the lack of effect seen in adaptive immunity by the deletion of RAGE, administration of the receptor decoy, sRAGE, still afforded a protective effect in RAGE-/- mice. Thus, sRAGE is likely to sequester ligands, thereby preventing their interaction with other receptors in addition to RAGE. These data suggest that, just as RAGE is a multiligand receptor, its ligands are also likely to recognize several receptors in mediating their biologic effects.</description><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Diabetes Mellitus - metabolism</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>General aspects</subject><subject>Glycation End Products, Advanced - metabolism</subject><subject>Humans</subject><subject>Immunity - physiology</subject><subject>Medical sciences</subject><subject>NF-kappa B - drug effects</subject><subject>NF-kappa B - metabolism</subject><subject>Receptor for Advanced Glycation End Products</subject><subject>Receptors, Immunologic - drug effects</subject><subject>Receptors, Immunologic - physiology</subject><subject>Signal Transduction - physiology</subject><issn>0946-2716</issn><issn>1432-1440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpdkMlKA0EQhhtRTFwewIsMgp4crV7SyzHEuIAgiJ6bnl7ihMlM7J4RfHs7JBDwUNTl-_8qPoQuMNxhAHGfADCoEmBSApeyFAdojBklJWYMDtEYFOMlEZiP0ElKy0yLiWLHaIQ5ppQRPkYPn63zMfWmdXW7KN6nT_Pbov_yRfTWr_suFiGPcT-mtd4Vi-bXmr7u2sK3rljHzg22T2foKJgm-fPdPkWfj_OP2XP5-vb0Mpu-lpYR0pdKeBWEsRNlgHkSlDfGWCqABm5YwEpJgq2VMlBJrHShElxVXLgKLA2e0VN0s-3Nh78Hn3q9qpP1TWNa3w1JcymUYmoDXv0Dl90Q2_ybJlgImHDCM4S3kI1dStEHvY71ysRfjUFv_OqtX5396o1fLXLmclc8VCvv9omd0Axc7wCTrGlCzN7qtOcEkQIkp384i4IR</recordid><startdate>20051101</startdate><enddate>20051101</enddate><creator>BIERHAUS, Angelika</creator><creator>HUMPERT, Per M</creator><creator>MORCOS, Michael</creator><creator>WENDT, Thoralf</creator><creator>CHAVAKIS, Triantafyllos</creator><creator>ARNOLD, Bernd</creator><creator>STERN, David M</creator><creator>NAWROTH, Peter P</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20051101</creationdate><title>Understanding RAGE, the receptor for advanced glycation end products</title><author>BIERHAUS, Angelika ; HUMPERT, Per M ; MORCOS, Michael ; WENDT, Thoralf ; CHAVAKIS, Triantafyllos ; ARNOLD, Bernd ; STERN, David M ; NAWROTH, Peter P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-97e9f7ac59a04e2f9eaaac3703f6a4f199821cc88f382c8dfb769b67db0c3fe43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Diabetes Mellitus - metabolism</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>General aspects</topic><topic>Glycation End Products, Advanced - metabolism</topic><topic>Humans</topic><topic>Immunity - physiology</topic><topic>Medical sciences</topic><topic>NF-kappa B - drug effects</topic><topic>NF-kappa B - metabolism</topic><topic>Receptor for Advanced Glycation End Products</topic><topic>Receptors, Immunologic - drug effects</topic><topic>Receptors, Immunologic - physiology</topic><topic>Signal Transduction - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BIERHAUS, Angelika</creatorcontrib><creatorcontrib>HUMPERT, Per M</creatorcontrib><creatorcontrib>MORCOS, Michael</creatorcontrib><creatorcontrib>WENDT, Thoralf</creatorcontrib><creatorcontrib>CHAVAKIS, Triantafyllos</creatorcontrib><creatorcontrib>ARNOLD, Bernd</creatorcontrib><creatorcontrib>STERN, David M</creatorcontrib><creatorcontrib>NAWROTH, Peter P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of molecular medicine (Berlin, Germany)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BIERHAUS, Angelika</au><au>HUMPERT, Per M</au><au>MORCOS, Michael</au><au>WENDT, Thoralf</au><au>CHAVAKIS, Triantafyllos</au><au>ARNOLD, Bernd</au><au>STERN, David M</au><au>NAWROTH, Peter P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Understanding RAGE, the receptor for advanced glycation end products</atitle><jtitle>Journal of molecular medicine (Berlin, Germany)</jtitle><addtitle>J Mol Med (Berl)</addtitle><date>2005-11-01</date><risdate>2005</risdate><volume>83</volume><issue>11</issue><spage>876</spage><epage>886</epage><pages>876-886</pages><issn>0946-2716</issn><eissn>1432-1440</eissn><abstract>Advanced glycation end products (AGEs), S100/calgranulins, HMGB1-proteins, amyloid-beta peptides, and the family of beta-sheet fibrils have been shown to contribute to a number of chronic diseases such as diabetes, amyloidoses, inflammatory conditions, and tumors by promoting cellular dysfunction via binding to cellular surface receptors. The receptor for AGEs (RAGE) is a multiligand receptor of the immunoglobulin superfamily of cell surface molecules acting as counter-receptor for these diverse molecules. Engagement of RAGE converts a brief pulse of cellular activation to sustained cellular dysfunction and tissue destruction. The involvement of RAGE in pathophysiologic processes has been demonstrated in murine models of chronic disease using either a receptor decoy such as soluble RAGE (sRAGE), RAGE neutralizing antibodies, or a dominant-negative form of the receptor. Studies with RAGE-/- mice confirmed that RAGE contributes, at least in part, to the development of late diabetic complications, such as neuropathy and nephropathy, macrovascular disease, and chronic inflammation. Furthermore, deletion of RAGE provided protection from the lethal effects of septic shock caused by cecal ligation and puncture (CLP). In contrast, deletion of RAGE had no effect on the host response in delayed-type hypersensitivity (DTH). Despite the lack of effect seen in adaptive immunity by the deletion of RAGE, administration of the receptor decoy, sRAGE, still afforded a protective effect in RAGE-/- mice. Thus, sRAGE is likely to sequester ligands, thereby preventing their interaction with other receptors in addition to RAGE. These data suggest that, just as RAGE is a multiligand receptor, its ligands are also likely to recognize several receptors in mediating their biologic effects.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>16133426</pmid><doi>10.1007/s00109-005-0688-7</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0946-2716
ispartof Journal of molecular medicine (Berlin, Germany), 2005-11, Vol.83 (11), p.876-886
issn 0946-2716
1432-1440
language eng
recordid cdi_proquest_miscellaneous_68799494
source Springer Nature:Jisc Collections:Springer Nature Read and Publish 2023-2025: Springer Reading List
subjects Animals
Biological and medical sciences
Chronic Disease
Diabetes Mellitus - metabolism
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
General aspects
Glycation End Products, Advanced - metabolism
Humans
Immunity - physiology
Medical sciences
NF-kappa B - drug effects
NF-kappa B - metabolism
Receptor for Advanced Glycation End Products
Receptors, Immunologic - drug effects
Receptors, Immunologic - physiology
Signal Transduction - physiology
title Understanding RAGE, the receptor for advanced glycation end products
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T21%3A27%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Understanding%20RAGE,%20the%20receptor%20for%20advanced%20glycation%20end%20products&rft.jtitle=Journal%20of%20molecular%20medicine%20(Berlin,%20Germany)&rft.au=BIERHAUS,%20Angelika&rft.date=2005-11-01&rft.volume=83&rft.issue=11&rft.spage=876&rft.epage=886&rft.pages=876-886&rft.issn=0946-2716&rft.eissn=1432-1440&rft_id=info:doi/10.1007/s00109-005-0688-7&rft_dat=%3Cproquest_cross%3E68799494%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c422t-97e9f7ac59a04e2f9eaaac3703f6a4f199821cc88f382c8dfb769b67db0c3fe43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=217705626&rft_id=info:pmid/16133426&rfr_iscdi=true